145 related articles for article (PubMed ID: 35060744)
1. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
Feng Z; Xiang J; Liu H; Li J; Xu X; Sun G; Zheng R; Zhang S; Liu J; Yang S; Xu Q; Wen X; Yuan H; Sun H; Dai L
J Med Chem; 2022 Feb; 65(3):2571-2592. PubMed ID: 35060744
[TBL] [Abstract][Full Text] [Related]
2. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases.
Feng Z; Xiang J; Sun G; Liu H; Wang Y; Liu X; Feng J; Xu Q; Wen X; Yuan H; Sun H; Dai L
J Med Chem; 2023 Jun; 66(11):7331-7354. PubMed ID: 37243609
[TBL] [Abstract][Full Text] [Related]
4. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease.
Li Z; Xu Y; Cai Z; Wang X; Ren Q; Zhou Z; Xie R
Bioorg Chem; 2020 Jun; 99():103803. PubMed ID: 32251945
[TBL] [Abstract][Full Text] [Related]
6. PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells.
Ke Q; Xiao Y; Liu D; Shi C; Shen R; Qin S; Jiang L; Yang J; Zhou Y
Biochem Pharmacol; 2024 Apr; 222():116076. PubMed ID: 38387308
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Okazaki S; Shioi R; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem; 2016 Nov; 24(21):5455-5461. PubMed ID: 27622746
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta.
Shen L; Zhang Y; Wang A; Sieber-McMaster E; Chen X; Pelton P; Xu JZ; Yang M; Zhu P; Zhou L; Reuman M; Hu Z; Russell R; Gibbs AC; Ross H; Demarest K; Murray WV; Kuo GH
J Med Chem; 2007 Aug; 50(16):3954-63. PubMed ID: 17608467
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM.
Ren Q; Deng L; Zhou Z; Wang X; Hu L; Xie R; Li Z
Bioorg Chem; 2020 Aug; 101():103963. PubMed ID: 32480174
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.
Shen L; Zhang Y; Wang A; Sieber-McMaster E; Chen X; Pelton P; Xu JZ; Yang M; Zhu P; Zhou L; Reuman M; Hu Z; Russell R; Gibbs AC; Ross H; Demarest K; Murray WV; Kuo GH
Bioorg Med Chem; 2008 Mar; 16(6):3321-41. PubMed ID: 18155554
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists.
Ban S; Kasuga J; Nakagome I; Nobusada H; Takayama F; Hirono S; Kawasaki H; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2011 May; 19(10):3183-91. PubMed ID: 21530275
[TBL] [Abstract][Full Text] [Related]
12. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
13. Design and Structural Optimization of Dual FXR/PPARδ Activators.
Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
[TBL] [Abstract][Full Text] [Related]
14. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
16. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
Kato T; Ohara T; Suzuki N; Muto S; Tokuyama R; Mizutani M; Fukasawa H; Matsumura KI; Itai A
Bioorg Med Chem Lett; 2022 Mar; 59():128567. PubMed ID: 35063634
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARδ agonists.
Luckhurst CA; Ratcliffe M; Stein L; Furber M; Botterell S; Laughton D; Tomlinson W; Weaver R; Chohan K; Walding A
Bioorg Med Chem Lett; 2011 Jan; 21(1):531-6. PubMed ID: 21075629
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease.
Yu DD; Van Citters G; Li H; Stoltz BM; Forman BM
Bioorg Med Chem; 2021 Jul; 41():116193. PubMed ID: 34022528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
